written on 17.03.2014

Will Three Decades of Growth in Small Molecule Generics be Followed by Biosimilars?


September will see the 30th anniversary of one of the most groundbreaking legislative acts affecting the US pharmaceutical industry – the Drug Price Competition and Patent Term Restoration Act of 1984, more commonly known as the Hatch-Waxman Act after its chief sponsors. In honor of this landmark industry development, the Thomson Reuter’s Generics Practice Area […]